The next generation of metabolic medicine isn't a drug. It's an ecosystem.

Microbiome-restoring metabolic medicines, built from precision-fermented plants and grain matrices.

CategoryEcological
SubstratePlant matrix
ArchitectureMulti-kingdom
I.
The problem

The GLP-1 era exposed an upstream restoration gap.

GLP-1 drugs activate one of the body's most important metabolic pathways. But metabolic disease is broader than one hormone receptor.

Patients still face GI tolerability issues, discontinuation, and weight regain after stopping.

The next generations of medicines will restore the gut ecosystem upstream of GLP-1.

II.
Category

A new therapeutic category.

What we are not
  • Probiotics.
  • Single-target drugs.
  • Receptor-first pharmacology.
What we are
  • Multi-kingdom ecology.
  • System-first medicine.
  • Endogenous signaling.
III.
Method

Our biotechnology turns plant matrices into standardized metabolic medicines.

i.

Optimal substrate design & activation.

Natural botanical substrates are conditioned through malting, hydration, milling, and thermal processing to create structured biological feedstock. First program: banana, millet, sorghum.

ii.

Precision ecological fermentation.

Bacteria, yeasts, and fungi are guided through controlled succession to convert the activated matrix into cross-feeding precursors which then create gut-relevant metabolites.

iii.

Clinical productization.

The payload is characterized, batch-tested, stabilized, and formulated as a physician-supervised metabolic intervention.

IV.
Why now

Four conditions have come into alignment.

i.

GLP-1 created the market.

Massive demand for metabolic intervention — but tolerability, discontinuation, and weight regain remain unsolved.

ii.

Human testing can move faster.

Food-grade plant matrices allow early clinical learning with short-cycle metabolic readouts.

iii.

AI makes ecology engineerable.

Computational biology can now map substrates, microbial communities, metabolite fingerprints, and patient response.

iv.

Commercial entry is possible now.

Medical-food and physician-supervised pathways create early revenue while building the human dataset.

V.
Platform reach

One platform. Multiple chronic disease markets.

Shared gut-axis biology enables capital-efficient expansion across indications.

1B+
Affected
Metabolic disease.
Pre-diabetes, type 2 diabetes, obesity.
30%
Affected
Liver disease.
NAFLD / NASH.
10–15%
Prevalence
GI disorders.
IBS.
25%
Affected
Gut–brain conditions.
Addiction, mental health.
VI.
The team

A team built for ecological therapeutics.

Computational biology. Ecological fermentation. Clinical translation.

Officers
Advisory Council
VN
CEO & Founder
Dr. Vivek Nandur
Computational biology. Developed the ecological-therapeutics thesis.
The founder behind Amara's ecological-therapeutics thesis.
BB
CPO
Brandon Boldt
10+ years production-scale ecological fermentation. Translates insights to manufactured products.
Production-scale fermentation expertise.
MH
CLO
Mikey Harrell
Early-stage and scaled operator (Cash App, BlockFi). Regulatory and commercialization pathway design.
Cash App · BlockFi · regulatory pathway design.
CN
COO
Cori Nandur
10+ years agtech operations. Scales systems into real-world production.
Agtech operations at production scale.
LO
CSO
Dr. Laura Ortiz
10+ years microbiome therapeutics. Bridges microbial ecology with clinical biology.
Microbiome therapeutics · clinical biology.
BS
Advisor · UCSD
Dr. Bernd Schnabl
Gastroenterology & hepatology. Gut-liver axis clinical expertise.
UCSD · gut-liver axis clinical authority.
RS
Advisor · MIT
Dr. Ram Sasisekharan
Biological engineering. Decades building biotech platforms.
MIT · decades of biotech platform building.
NG
Advisor · FGCU
Dr. Ned Gvozdic
Physical chemistry. Biotech patent expert with over 100 patents.
FGCU · 100+ biotech patents.